Comparative Pharmacology
Head-to-head clinical analysis: ERYGEL versus PROKLAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYGEL versus PROKLAR.
ERYGEL vs PROKLAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking the translocation of peptidyl-tRNA.
PROKLAR (clarithromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
Apply a thin layer to affected areas twice daily. Topical use only.
500 mg orally every 12 hours for 7-14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 1.6 hours (range 1.0–2.5 hours) after topical application, too short to accumulate with daily use.
Terminal elimination half-life: 2-4 hours (prolonged to 6-8 hours in hepatic impairment); context: requires q8-12h dosing in normal renal function
Primarily hepatic metabolism; less than 10% excreted renally as unchanged drug. Biliary excretion is minimal.
Renal: 20-30% unchanged; fecal: 15-30%; biliary: 5-10%; total renal excretion of metabolites: ~70%
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic